Mind Medicine completes enrollment in Phase 2a study to treat adults with ADHD

Mind Medicine announced that it has completed enrollment of Study MMED007, the Company’s Phase 2a study evaluating repeated low-dose administration of MM-120 or lysergide D-tartrate, for the treatment of adults with ADHD. “We are pleased to announce the completion of enrollment of our Phase 2a study in adults with ADHD,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “This proof-of-concept trial is designed to evaluate the clinical effects of a sub-perceptual dose of MM-120 administered in a repeated fashion. The study’s results will inform our ongoing work to establish new clinical paradigms for this promising drug candidate. We anticipate sharing topline data by the end of the first quarter of 2024.” MMED007 is a multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MM-120 compared with a placebo administered orally twice weekly for 6 weeks in adults between the ages of 18 and 65 with ADHD. The primary endpoint in this study is mean change from Baseline in ADHD symptoms, as assessed by the Adult ADHD Investigator Symptom Rating Scale AISRS after 6 weeks of treatment. Key secondary objectives, measured up to 10 weeks after the initial dose, include assessments of ADHD symptom severity, as well as safety and tolerability.